Led · Equity · Apr 2026

Launched in 2023, Serve First offers an AI-driven CX and performance intelligence platform that combines customer feedback, mystery shopping, operational audits and real-time action management into a single system. Its software translates insights into actions for frontline teams and is used across retail, hospitality, health & wellness, franchise and facilities management. Key customers include Alphega Pharmacy, Aramark and Elior Group, and newer wins include Brentford FC, The Sushi Co, Topps Tiles, The Body Shop and Spud Bros. The company reports that annual recurring revenue has almost doubled to over €2.2 million and has secured a European contract with a chain of more than 2,500 pharmacies across seven countries. Serve First plans to use the new funding to expand sales and marketing (including appointing a Chief Revenue Officer) and to continue product and AI capability development.

Led · Equity · Feb 2026

Neupulse is a University of Nottingham spin-out focused on bringing to market a non-invasive wristband that eases motor and vocal tics associated with Tourette’s syndrome. The device delivers targeted stimulation intended to provide a drug-free alternative to medication and behavioural therapy, addressing a significant unmet clinical need that affects up to 2 % of children worldwide. Recent funding allows the company to progress product development, build its regulatory dossier and expand clinical evidence in preparation for launch. Management plans a mid-2026 commercial debut in the UK before scaling internationally. The £3 m raised follows a £500 k investment from the Midlands Engine Investment Fund II in 2024, giving the team additional runway for trials and early commercialisation activities. Investors highlight the technology’s global impact potential and the strong research pedigree underpinning the product.

Led · Equity · Feb 2026

NuVision Biotherapies develops and manufactures amniotic-membrane–based solutions for ophthalmology. Its dual-patented Tereo Process enables scalable processing of amniotic membrane, forming the basis of its product line. The company’s first product, Omnigen, is used in operating theatres, while OmniLenz, a specialised contact lens, delivers the same therapy without surgery, extending treatment to opticians’ practices and outpatient clinics. NuVision now supplies more than 160 NHS centres and private clinics in the UK, including Moorfields Eye Hospital, and serves customers in 12 countries across Europe, Scandinavia and the Middle East. Founded by Dr. Andy Hopkinson, the company is focused on expanding operations and further product development. The newly secured capital will finance this expansion as NuVision seeks broader international reach and additional clinical applications for its technology.

Participated · Equity · Jan 2026

Gutology is a UK-based oral-care company that focuses on products formulated to support both oral and gut microbiomes. Its flagship Oral Biome+ toothpaste combines hydroxyapatite (a natural enamel mineral) with Truebiotic parabiotics to promote microbial balance. The firm sells a full oral-care range directly to consumers online and through specialist health stores. Currently employing ten staff at its Alcester, Warwickshire headquarters, Gutology plans to forge partnerships with major retailers to broaden distribution. The company also intends to expand geographically into the United States and Germany. Part of the newly raised capital will fund clinical research aimed at developing additional microbiome-friendly products. Although specific revenue or user metrics were not disclosed, the company’s growth strategy centers on international expansion and product pipeline development.

Led · Equity · Oct 2025

Forge Genetics has created a proprietary gene-editing platform that offers higher targeting accuracy than CRISPR, enabling more bacterial cells to survive editing and functioning across a broader spectrum of bacterial strains. The technology can also detect and filter out unwanted DNA mutations, positioning it as a potentially safer approach for editing human cells. Currently, the company monetizes the tool through contract research services for pharmaceutical and biotechnology clients and has generated over £2.2 million in commercial business in under two years. Headquartered at the University of Nottingham, Forge Genetics was founded by Professor Nigel Minton, Dr Chris Humphreys, and Dr Craig Woods, later joined by Dr Lisa Thomas. The firm employs 10 people and plans to double its headcount within the next two years. New funding will be directed toward expanding commercial strain-development projects and adapting the platform for use in human and animal cells, broadening its market reach.